Drug Profile
PPI 461
Alternative Names: PPI-0461; PPI-461Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Presidio Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in Denmark (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in United Kingdom (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in USA (PO, Capsule)